- Home
- AGEN vs NPT Comparison
AGEN vs NPT Comparison
Compare AGEN & NPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | NPT |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 126.9M |
| IPO Year | 2000 | 2025 |
Fundamental Metrics
Financial Performance| Metric | AGEN | NPT |
|---|---|---|
| Price | $3.23 | $5.66 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 901.2K | 65.0K |
| Earning Date | 03-10-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $106,829,000.00 | ★ $797,148,640.00 |
| Revenue This Year | $23.68 | N/A |
| Revenue Next Year | $23.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.51 |
| 52 Week Low | $1.38 | $3.14 |
| 52 Week High | $7.34 | $9.18 |
Technical Indicators
Market Signals| Indicator | AGEN | NPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | N/A |
| Support Level | $3.12 | N/A |
| Resistance Level | $3.55 | N/A |
| Average True Range (ATR) | 0.38 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 6.57 | 0.00 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.